Repligen (RGEN)
(Delayed Data from NSDQ)
$161.67 USD
-4.00 (-2.41%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $161.66 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 141 - 160 ( 208 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Modeling COVID-19: Vaccine and Diagnostic Demand Outlook with Herd Immunity in 2021
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Bioproduction: FDA Advisory Committee COVID-19 Vaccine Hearing Highlights
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Overweight - The ''Cinderella of Bioprocessing''
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Steady as a Rock; Robust 2Q20 Results; Raising PT to $168
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
EMT Acquisition Provides Tuck-in Value; Reiterate Buy; Raising PT to $151
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Financials Reported; Trucking Blithely Onward; Raising PT to $143
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R